<sup>123</sup>I-FP-CIT SPECT was performed at a single-center level on 370 individuals with PS, including 280 patients with Parkinson's disease (PD), 21 with multiple system atrophy-parkinsonian type (MSA-P), 41 with progressive supranuclear palsy (PSP) and 28 with corticobasal syndrome (CBS) (mean age 70.3 years, 47% female, mean disease duration at scan 1.4 year), as well as 208 age- and gender-matched control subjects.
The utility of the combined use of <sup>123</sup>I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes.
This study aims to investigate the patterns of striatal <sup>18</sup>F-FP-CIT uptake in patients with AD-related cognitive impairment (ADCI) with mild parkinsonism.
To evaluate the value of I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) to change management strategies of patients suspected of parkinsonism.
A combination of cardiac <sup>123</sup>I-meta-iodobenzylguanidine scintigraphy and <sup>123</sup>I-FP-CIT single-photon emission computed tomography imaging, in addition to brain magnetic resonance imaging findings, helped to discriminate MSA-P from other sources of parkinsonism.
We aimed at examining sensitivity of combined visual and semi-quantitative <sup>123</sup>I-FP-CIT SPECT analyses in a prospective cohort of subjects with DLB and degenerative parkinsonisms - Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) to determine prevalence and clinical significance of scans without evidence of dopaminergic deficit (SWEDD).
Usefulness of combining <sup>123</sup>I-FP-CIT-SPECT striatal asymmetry index and cardiac <sup>123</sup>I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms.
Patients with mild parkinsonian symptoms, excellent response to low dosages of dopaminergic drugs and a reduced dopamine-transporter uptake in [(123)I] FP-CIT-SPECT might more commonly be GCH1 mutation carriers than has previously been supposed.